Cediranib
Recurrent Plasma Cell Myeloma
Ohio State University Comprehensive Cancer CenterSmall moleculePhase 2Active
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Recurrent Plasma Cell Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Leflunomide City of Hope Medical Center | Phase 2 | BB |
Dinaciclib National Cancer Institute (NCI) | Phase 2 | B |
Pelareorep University of Southern California | Phase 1/2 | B |
Metformin Mayo Clinic | Phase 2 | B |
lcl161 Mayo Clinic | Phase 2 | B |
View all 41 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →